|
In the News The Burrill Report interviews Greg Scott on WuXi/CRL breakup and China IPOs
Greg Scott joined Foley's Eye on China webinar on innovation
>>Foley webinar... Event News 2nd Annual ChinaBio Partnering Forum attracts 558 attendees to Suzhou... more >>
ChinaBio® Events
BioBay Investor Forum 2010Suzhou, ChinaNov. 3-4, 2010
China Forum 2010Munich, GermanyNovember 14, 2010
ChinaBio® Investor Forum 2010 - GuangzhouGuangzhou, ChinaDecember 21, 2010Latest Headlines ChinaBio® Today
Free Newsletter ChinaBio® Today
Partner Events
BioPharm America™ 2010Boston, MA, USASeptember 15–17, 2010
CALAsia 2010San Diego, USAOctober 4-5, 2010 |
CRO/CMO ServicesChinaBio® works with drug delevelopment companies seeking to drive down their development costs by leveraging the CRO/CMO providers in China, where costs can be as little as 20% of that in the U.S. or Europe. Our CRO/CMO Services group can help companies identify and select high quality CROs/CMOs in China, negotiate a sound contract, and oversee the project to ensure success. We can also assist with developing a global development strategy that best leverages China's capabilities, while avoiding potential weaknesses. Identification and Selection ChinaBio® has developed a proprietary list of over 260 CROs and CMOs in China to help companies identify potential partners in China. More importantly, we have met with senior management and reviewed the specific capabilities of the 40 leading firms, giving us deep insight into the CRO/CMO landscape in China. We work closely with our clients to define the specific requirements for the study and help refine study designs to fit China's capabilities. We then identify potential partners that have the ability to meet the study requirements and perform a capabilities review to ensure that the candidate CROs/CMOs meet the client's expectation. Our team based in China can also assist with due diligence activities, saving our clients multiple trips to China. Contract Assistance Once the partner is selected, ChinaBio® can assist with contract negotiations. Our team has negotiated over 30 outsourcing and services agreements for major pharma and biotechs, with contracts valued at up to $720 million USD. And our bi-lingual team understands the subtleties involved in complex, cross-border, cross-cultural agreements, and can ensure that there is a solid business understanding between the parties. Project Execution But the signing of the agreement is only the beginning - over the next few months or even years, ChinaBio® works with its clients to ensure that the study plan and execution delivers the quality data and products our clients' expect. Our highly experienced team of CMC, pre-clinical and clinical experts based in the US brings deep expertise in planning and monitoring studies to ensure they meet global standards, while our on-the-ground project managers in China monitor the day-to-day project to ensure high quality delivery. Executive Oversight While regular monitoring is vital for project success, having our executive management team based in China enables us to meet with senior leadership of the service providers to ensure all parties are working together toward a common goal, and to address any issues that may arise at the highest levels. If you are seeking a CRO/CMO partner in China, ChinaBio® can help ensure your project's success. Please contact us for more information.
|